Search

Showing 1 - 10 of 449 results.

Clinical Data

SWITCH TO THE REFERRAL VIEW For more information specific to neurology regarding PFO closure FIND OUT MORE: DOWNLOAD ESOC PRESENTATION Download data summary Downloa
Connext

Therapies Valvular Diseases Mitral Valve Disease Aortic Valve Disease Tricuspid Valvle Disease Paravalvular Leak
CS Webinar 2025

ABBOTT CS WEBINARS 2025 Join us for our Aortic and Mitral Valve Replacement Webinar Series, where experts will discuss the latest advancements in valvular heart disease management. These sessions w
TMTI Landingpage

TRICLIP™ TEER SIGNIFICANT, SUSTAINED TR REDUCTION The controlled and stable closing mechanism delivers sustained annular reduction.7-10 MITRACLIP™ TEER ¶ Statistically significant change from b
Patients who benefit

A STATE-OF-THE-ART TREATMENT OPTION FOR PATIENTS AT HIGH RISK FOR SURGERY TriClip™ TEER is a low risk,5 minimally invasive, non-surgical treatment option for symptomatic patients with severe Tricuspi
Features

MITRACLIP™ SUCCESSFULLY TREATS A BROAD RANGE OF VALVE ANATOMIES IN REAL-WORLD USE8,9 NEARLY 1 IN 5 PATIENTS TREATED HAVE VALVE ANATOMIES CONSIDERED COMPLEX8 Valve anatomies include: presence
Patients who benefit

49% of patients with symptomatic severe MR were not operated due to age, co-morbidities, or impaired LV.5 If left untreated, MR initiates a cascade of events leading to death, with 1-year mortali
TMTI Durability campaign

Stone et al., 2023 NEJM COAPT 5-Year Outcome. Feldman et al., 2015 JACC 5 Yr EVEREST II RCT. Nickenig et al., 2024 JACC 3-Year Outcomes from the TRILUMINATE Study. SHARE YOUR LONGEST TEER FOLL
Overview

WATCH HOW MITRACLIP™ TEER TRANSFORMED LUCA'S LIFE FIND OUT MORE: DOWNLOAD FLYER FIND OUT MORE: EuroPCR Symposium 2025 EuroPCR 2025 EXPANDed Podium deck EuroPCR 2025 EXPANDed E-Po
Overview

2-Year OUTCOMES from the triluminate pivotal trial New TriClip™ Transcatheter Edge-to-Edge Repair clinical data release EXPLORE NOW WATCH HOW TRICLIP™ TEER TRANSFORMED CRUZ'S LIFE FIND